MFSD4B

Across TCGA pan-cancer cohorts, MFSD4B RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MFSD4B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MFSD4B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MFSD4B is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, KIRC, and KIRP are the cancer types where MFSD4B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MFSD4B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+1.126	<.001	12	view →
KIRC	Male	All	+0.644	<.001	12	view →
KIRP	All	II,III,IV	+0.885	<.001	11	view →
HNSC	Male	All	+0.693	<.001	11	view →
STAD	All	II,III,IV	+0.718	<.001	9	view →
KICH	Female	II,III,IV	−1.192	<.001	8	view →
THCA	All	II,III,IV	−0.419	<.001	8	view →
LUSC	All	II,III,IV	+0.523	<.001	6	view →
LUAD	All	All	+0.420	<.001	6	view →
LIHC	All	All	+0.296	<.001	6	view →
UCEC	All	III,IV	+0.648	.037	4	view →
CHOL	All	All	+0.846	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MFSD4B–BLCA

Open the BLCA breakdown →